When it comes to finding ultimate solutions for some of mankind’s most troubling medical issues, healthcare professionals have to come together. This is the only way for scientists to have a chance at destroying a disease. And even then, it takes nearly immeasurable amounts of commitment to see it through. All of the administration, practice, service, along with research and development, has to fall under some form of leadership.
When it comes to the advances made by Expansion Therapeutics, Scott Rocklage is just one pioneer among many who deserves a word or two of notice. Their assault on ailment starts with serious amounts of Series A financial resources. These monies are for combating genetic disorders, more specifically Myotonic Dystrophy type l (DM1). Toxic levels of RNA is the underlying cause for this medical condition.
It is a 35 million dollar project that brings together Sanofi Ventures, Novartis Venture Fund, Kleiner Perkins, 5AM Ventures, Alexandria Venture Investments and RA Capital Management. It should take a team of this size to take on DM1, because the disease itself affects more than one part of the body. The the heart along with the respiratory, gastrointestinal, hormonal and central nervous systems are vulnerable to DM1. The worst part about this particular disease is that it can affect whole families, and modern medicine has no effective treatment for it.
Suffice it to say that there is nowhere to go but up from the current circumstances surrounding treatment. And that is precisely where Scott Rocklage and 5AM Ventures come in to play. The ability to conduct medical research and find breakthroughs often requires someone to rally institutions and professionals around the goings on in the laboratory.
This gathering of establishments to projects is the service Rocklage and 5AM Ventures provide. He has more than three decades of experience with finding financial solutions for doctors who are finding medical solutions for patients. As a matter of fact, he holds more than one leadership role in other organizations such as Board Chairman for Cidara, Kinestral and Rennovia.
Connect with Scott Rocklage on LinkedIn.